Phase 3 Start

CLRB: Phase3_Start: An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor

Name: Phase3_Start: An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor
Start: 2026-12-01
End: 2026-12-01

December 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2026
Company: Cellectar Biosciences, Inc. (CLRB)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Start

Phase3_Start: An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor

December 1, 2026

CLRB overview →

Company: Cellectar Biosciences, Inc. (CLRB)